Panthera Wins Contract to Recruit Patients for Roche Breast Cancer Study
Panthera Biopartners continues to grow its pipeline of oncology studies. The latest study now underway is a Roche phase III double-blind placebo-controlled study for advanced or metastatic breast cancer patients.
Panthera will be recruiting from three sites in the UK in Liverpool, Reading and Newport via their partnership with Rutherford Health. This global multicentre trial which will run for up to five years is targeted at breast cancer patients with a PIK3CA mutation.
Panthera Biopartners which was only founded two and a half years ago now has a network of nine sites across the UK and a growing pipeline of commercial clinical trials in both oncology and general medicine, including eight oncology studies open or in set up. Panthera has a new site in development in Sheffield and has recently expanded its sites in Preston, North London and Glasgow.
Stuart Young Chief Executive of Panthera commented “We are really pleased to be involved in this pivotal new study with the recruitment of patients already underway. We have been delighted by the response from CROs and pharma to our new model of recruiting patients and delivering high quality clinical trials and are continuing to grow our organisation to meet this demand. While our expansion continues in the UK we are now in discussions on sites in Europe”.
Panthera was founded by Dr Ian Smith, founder of Synexus, and John Lyon, previously a senior executive at Covance. The network of sites, which will continue to expand, can undertake trials in conditions treated in primary care such as Cardiac disease, Osteoarthritis, Osteoporosis, Diabetes, Allergies and Migraine, we well as specialist therapy areas including neurology, oncology, vaccines, and NASH.